Genscript Biotech's total inventories for the quarter that ended in Dec. 2025 was $39.6 Mil. Genscript Biotech's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was $39.2 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Genscript Biotech's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $0.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Genscript Biotech's Days Inventory for the
six
months ended in Dec. 2025 was 34.36.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Genscript Biotech's Inventory Turnover for the quarter that ended in Dec. 2025 was 5.31.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genscript Biotech's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.09.
Genscript Biotech (OTCPK:GNNSF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Genscript Biotech's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Genscript Biotech's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Genscript Biotech Total Inventories Related Terms
Genscript Biotech Total Inventories Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Genscript Biotech (GNNSF) has a Total Inventories of $39.6 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors.
Is Genscript Biotech's Total Inventories too high?
Genscript Biotech's current Total Inventories is $39.6 Mil. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Total Inventories compare to VRTX and REGN?
Genscript Biotech's Total Inventories of $39.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors. Genscript Biotech's current Total Inventories is $39.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Total Inventories is $39.6 Mil. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Total Inventories is $39.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Total Inventories: $39.6 Mil
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
